Everolimus inhibits breast cancer cell growth through PI3K/AKT/mTOR signaling pathway

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• Breast cancer is a leading cause of cancer mortality globally, necessitating novel therapeutic strategies.
• Everolimus, an mTOR inhibitor, shows promise as an anti-cancer agent.
• Understanding the precise mechanisms of everolimus in breast cancer is crucial for optimizing its clinical application.

Purpose of the Study:

• To investigate the inhibitory effects of everolimus on breast cancer cell proliferation, migration, and invasion.
• To elucidate the molecular mechanisms underlying everolimus-mediated anti-cancer effects.
• To evaluate the efficacy of everolimus in an in vivo mouse model of breast cancer.

Main Methods:

• In vitro studies using breast cancer cell lines (MCF-7) to assess cell growth, migration, and invasion.
• Apoptosis assays and Western blotting to analyze key protein expression levels (Bcl-2, Bcl-w, Caspase-3, Caspase-8, PI3K, AKT, mTOR).
• In vivo experiments using an MCF-7 xenograft mouse model to evaluate tumor growth inhibition.

Main Results:

• Everolimus significantly inhibited breast cancer cell growth, migration, and invasion in vitro.
• Everolimus induced apoptosis by modulating Bcl-2, Bcl-w, Caspase-3, and Caspase-8 expression.
• The drug suppressed the PI3K/AKT/mTOR signaling pathway, and PI3K overexpression counteracted its effects.
• In vivo, everolimus markedly inhibited tumor growth in the MCF-7 bearing mouse model.

Conclusions:

• Everolimus demonstrates potent anti-cancer activity against breast cancer cells and in vivo tumor models.
• The PI3K/AKT/mTOR signaling pathway is a key mediator of everolimus's inhibitory effects.
• These findings suggest that targeting the PI3K/AKT/mTOR pathway with everolimus is a promising therapeutic strategy for breast cancer.